The preparation, characterization of Lupeol PEGylated liposome and its functional evaluation in vitro as well as pharmacokinetics in rats

Reference

• Chen L, Guo PA, He YC, et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelialmesenchymal transition through MAPK/ERK signalling pathway. Cell Death Dis. 2018;9:513.
   PubMed Web of Science ®Google Scholar
• Guarino M, Bruzzese D, Di Costanzo GG, et al. HCC recurrence after DAA treatment in HCV patients. Digest Liver Dis. 2018;50:50.
   Web of Science ®Google Scholar
• Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–1391.
   PubMed Web of Science ®Google Scholar
• Wei M, Guo X, Tu L, et al. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Int J Nanomed. 2015;10:5123–5137.
   PubMed Web of Science ®Google Scholar
• da Silva ICV, Kaluderovic G, de Oliveira PF, et al. Apoptosis caused by triterpenes and phytosterols and antioxidant activity of an enriched flavonoid extract and from Passiflora mucronata. Anticancer Agents Med Chem. 2018;18:1405–1416.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Zhang L, et al. Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest. 2009;27:163–170.
   PubMed Web of Science ®Google Scholar
• Lee TK, Castilho A, Cheung VC, et al. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology. 2011;53:160–170.
   PubMed Web of Science ®Google Scholar
• Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009;285:109–115.
   PubMed Web of Science ®Google Scholar
• Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008;10:475–510.
   PubMed Web of Science ®Google Scholar
• Chaturvedi PK, Bhui K, Shukla Y. Lupeol: connotations for chemoprevention. Cancer Lett. 2008;263:1–13.
   PubMed Web of Science ®Google Scholar
• Saleem M, Afaq F, Adhami VM, et al. Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene. 2004;23:5203–5214.
   PubMed Web of Science ®Google Scholar
• Siddique HR, Saleem M. Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci. 2011;88:285–293.
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res. 2007;24:2402–2411.
   PubMed Web of Science ®Google Scholar
• Yu F, Tang X. Novel long-circulating liposomes consisting of PEG modified β-sitosterol for gambogic acid delivery. J Nanosci Nanotechnol. 2016;16:3115–3121.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang H, Yu M, et al. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Pharm Res. 2010;27:1914–1926.
   PubMed Web of Science ®Google Scholar
• Meng S, Su B, Li W, et al. Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol. 2011;28:1180–1187.
   PubMed Web of Science ®Google Scholar
• Yang G, Yang T, Zhang WD, et al. In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome. J Agric Food Chem. 2014;62:2207–2215.
   PubMed Web of Science ®Google Scholar
• Priyanka K, Kosuru R, Sharma RP, et al. Assessment of pharmacokinetic parameters of lupeol in Ficus religiosa L. extract after oral administration of suspension and solid lipid nanoparticles to Wistar rats. J Drug Deliv Sci Tec. 2017;41:58–67.
   Web of Science ®Google Scholar
• Sharma A, Mayhew E, Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 1993;53:5877–5881.
   PubMed Web of Science ®Google Scholar
• Balasubramanian SV, Straubinger RM. Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. Biochemistry. 1994;33:8941–8947.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma US, Straubinger RM. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996;107:265–272.
   PubMed Web of Science ®Google Scholar
• Li JH, Li B, Jiang HR, et al. Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma. Zhonghua Zhong Liu za Zhi [Chinese J Oncol]. 2011;33:229–231.
   PubMedGoogle Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1:297–315.
   PubMed Web of Science ®Google Scholar
• Mima Y, Abu Lila AS, Shimizu T, et al. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. J Control Release. 2017;250:20–26.
   PubMed Web of Science ®Google Scholar
• Furuhata M, Izumisawa T, Kawakami H, et al. Decaarginine-PEG-liposome enhanced transfection efficiency and function of arginine length and PEG. Int J Pharm. 2009;371:40–46.
   PubMedGoogle Scholar
• Li H, Yuan D, Sun M, et al. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo. Drug Deliv. 2016;23:3562–3572.
   PubMed Web of Science ®Google Scholar
• Cai L, Wang X, Wang W, et al. Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo. Int J Nanomed. 2012;7:4499–4510.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9:E128–E147.
   PubMed Web of Science ®Google Scholar
• Dong F, Valsami-Jones E, Kreft JU. New, rapid method to measure dissolved silver concentration in silver nanoparticle suspensions by aggregation combined with centrifugation. J Nanopart Res 2016;18:259.
   PubMed Web of Science ®Google Scholar
• Hu JJ, Li X, Zhou JX, et al. Celastrol delays hepatic steatosis and carcinogenesis in a rapid AKT/c-Met-transfected hepatocellular carcinoma model via suppressing fatty acid synthase expression and AKT/ERK phosphorylation. RSC Adv. 2018;8:13976–13983.
   PubMed Web of Science ®Google Scholar
• Rawat P, Ahmad I, Thomas SC, et al. Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: pharmacokinetic and biochemical assessment. Int J Pharm. 2016;506:253–261.
   PubMed Web of Science ®Google Scholar
• Tan MC, Matsuoka S, Ano H, et al. Interaction kinetics of liposome-incorporated unsaturated fatty acids with fatty acid-binding protein 3 by surface plasmon resonance. Bioorg Med Chem. 2014;22:1804–1808.
   PubMed Web of Science ®Google Scholar
• Kang JH, Jang WY, Ko YT. The effect of surface charges on the cellular uptake of liposomes investigated by live cell imaging. Pharm Res. 2017;34:704–717.
   PubMed Web of Science ®Google Scholar
• Li HJ, Du JZ, Du XJ, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci USA. 2016;113:4164–4169.
   PubMed Web of Science ®Google Scholar
• Gubernator J, Chwastek G, Korycińska M, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release. 2010;146:68–75.
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14:301–308.
   PubMed Web of Science ®Google Scholar
• El Kateb N, Cynober L, Chaumeil JC, et al. L-cysteine encapsulation in liposomes: effect of phospholipids nature on entrapment efficiency and stability. J Microencapsul. 2008;25:399–413.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin A, Peng P, et al. Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes. Drug Deliv. 2016;23:1426–1433.
   PubMed Web of Science ®Google Scholar
• Yoshizawa Y, Kono Y, Ogawara K, et al. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412:132–141.
   PubMed Web of Science ®Google Scholar
• Ulukaya E, Ozdikicioglu F, Oral AY, et al. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol in Vitro. 2008;22:232–239.
   PubMed Web of Science ®Google Scholar
• Liang CZ, Zhang JK, Shi Z, et al. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol. 2012;69:317–331.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bi T, Dai W, et al. Lupeol induces apoptosis and cell cycle arrest of human osteosarcoma cells through PI3K/AKT/mTOR pathway. Technol Cancer Res Treat. 2016;15:NP16–NP24.
   PubMed Web of Science ®Google Scholar
• Hagiwara K, Kurihara K, Honma M, et al. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect. J Biomat Sci-Polym E. 2018;29:448–459.
   PubMed Web of Science ®Google Scholar